Daiichi Sankyo Earnings: Brisk Start to Fiscal 2025 Driven by Enhertu's Ongoing Sales Ramp-Up Jay Lee Jul 31, 2025 ...

The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd. The gist of the safety ...

(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that the Food and Drug Administration has accepted and granted Priority Review to the supplemental Biologics ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...

In July, Daiichi and AZ reported combined Enhertu sales of $893 million for 2024’s second quarter, reflecting a scant 1.6% sequential increase from the first three months of the year.

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

AstraZeneca and Daiichi Sankyo began their ADC alliance in 2019, focused initially on Enhertu. The following year, the companies inked a partnership on datopotamab deruxtecan, which had the code ...

Enhertu reduced the risk of disease progression or death by 36%, with a median PFS of 13.2 months versus 8.1 months for chemotherapy. The trial showed an ORR of 62.6% for Enhertu compared to 34.4% ...

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...

Additionally, Daiichi Sankyo and its Enhertu commercial partner AstraZeneca demonstrated excellent commercial decision-making by pursuing approval for the newly defined HER2-Low breast cancer ...